Results 121 to 130 of about 5,546 (214)

Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumourchemoresistance

, 2015
International audiencePancreatic ductal adenocarcinoma (PDAC) is extremely stroma-rich. Cancer-associated fibroblasts (CAFs) secrete proteins that activate survival and promote chemoresistance of cancer cells.
Aurélie Perraud, Buscail L, Camille Duluc, Corinne Bousquet, Florence Breibach, Herbert Schmid, Marie‐Bernadette Delisle, Marie‐Pierre Bousquet‐Dubouch, Marion Gayral, Mounira Chalabi‐Dchar, Muriel Mathonnet, Pierre Cordelier, Richard Tomasini, Rémi Samain, Siham Moatassim‐Billah, Stéphane Pyronnet, Yvan Martineau   +16 more
core   +4 more sources

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study [PDF]

, 2020
Annamaria Colao, Marcello D. Bronstein, Thierry Brue, Laura De Marinis, Maria Fleseriu, Mirtha Guitelman, Gérald Raverot, Ilan Shimon, J Fleck, Pritam Gupta, Alberto M Pedroncelli, Mônica R. Gadelha   +11 more
openalex   +1 more source

Glucagon Secreting Tumors and Glucagonoma Syndrome [PDF]

, 2017
Glucagonomas are the functioning neuroendocrine tumors. These arise from pancreatic islet α-cells. These tumors are extremely rare and have an annual incidence of 1 per 20-40 million population 80% of glucagon-expressing tumors are sporadic, and 20% are ...
Bano, G, Beharry, N, Du Parc, J, Khalid, Y, Mudan, S, Ozair, F   +5 more
core  

Enfermedad de Cushing: correlación clínica y molecular [PDF]

, 2015
Premio extraordinario de Trabajo Fin de Máster curso 2012-2013.Investigación Biomédica TraslacionalLa enfermedad de Cushing es la causa más frecuente de síndrome de Cushing endógeno.
Moreno Moreno, Paloma
core  

Pasireotide prevents nuclear factor of activated T cells nuclear translocation and acts as a protective agent in aminoglycoside‐induced auditory hair cell loss [PDF]

, 2016
Daniel Bodmer, Adrijana Perkovic, Marijana Sekulic‐Jablanovic, Matthew B. Wright, Vesna Petkovic   +4 more
openalex   +1 more source

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly [PDF]

, 2016

core   +1 more source

Effects and Side Effects of Pasireotide Treatment in Cushing’s Disease: Experience of a Single Tertiary Center

, 2021
Hande Mefkure Özkaya, Serdar Şahin, Güler Kerimova, Emre Durcan, Cem Sulu, Pınar Kadıoğlu   +5 more
openalex   +1 more source

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma

Journal of Hepatocellular Carcinoma, 2018
Lynn G Feun,¹ Medhi Wangpaichitr,² Ying-Ying Li,¹ Deukwoo Kwon,³ Stephen P Richman,¹ Peter J Hosein,¹ Niramol Savaraj¹,² ¹Department of Medicine, Medical Oncology, Sylvester Comprehensive Cancer Center ...
Feun LG, Wangpaichitr M, Li YY, Kwon D, Richman SP, Hosein PJ, Savaraj N   +6 more
doaj  

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

, 2019
M.H. Kulke, P. Ruszniewski, E. Van Cutsem, Catherine Lombard‐Bohas, J.W. Valle, W.W. De Herder, Marianne Pavel, E. Degtyarev, J.C. Brase, Lida Bubuteishvili‐Pacaud, M. Voi, R. Salazar, Ivan Borbath, Nicola Fazio, D. Smith, J. Capdevila, Rachel P. Riechelmann, J.C. Yao   +17 more
openalex   +1 more source

Potential antitumour activity of pasireotide on pituitary tumours in acromegaly [PDF]

, 2019
Eva C Coopmans, A. J. van der Lely, J.J. Schneiders, Sebastian Neggers   +3 more
openalex   +1 more source